Novo Nordisk and Merrion partnered to use Merrion's GIPET absorption-enhancing technology to boost the oral bioavailability of a Novo Nordisk diabetes compound

Merrion Pharmaceuticals plc

Ireland / Small-Cap Biopharma (<$1 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Novo Nordisk A/S

Denmark / Large-Cap Biopharma (>=$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Terminated

Sample

01/01/2009

announced

01/01/2009

Terminated